tetano
Editor, Senior Moderator
Intern Med
. 2022 Aug 10.
doi: 10.2169/internalmedicine.0104-22. Online ahead of print.
A Novel Development of Sarcoidosis following COVID-19 Vaccination and a Literature Review
Tadahisa Numakura[SUP] 1 [/SUP], Koji Murakami[SUP] 1 [/SUP], Tsutomu Tamada[SUP] 1 [/SUP], Chiaki Yamaguchi[SUP] 2 [/SUP], Chihiro Inoue[SUP] 3 [/SUP], Shinya Ohkouchi[SUP] 4 [/SUP], Naoki Tode[SUP] 1 [/SUP], Hirohito Sano[SUP] 1 [/SUP], Hiroyuki Aizawa[SUP] 1 [/SUP], Kei Sato[SUP] 1 [/SUP], Ayumi Mitsune[SUP] 1 [/SUP], Hajime Kurosawa[SUP] 4 [/SUP], Toru Nakazawa[SUP] 2 [/SUP], Hisatoshi Sugiura[SUP] 1 [/SUP]
Affiliations
Abstract
BNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. However, immunological adverse events due to mRNA vaccines in real-world settings are not fully known. We herein report the novel development of sarcoidosis manifested as uveitis, bilateral hilar lymphadenopathy, angiotensin-converting enzyme elevation, and epithelioid and giant cell granuloma formation in the lung soon after the first BNT162b2 injection and review the current literature, including three reported cases of sarcoid-like reaction following COVID-19 vaccination.
Keywords: COVID-19; Sarcoidosis; Uveitis; angiotensin-converting enzyme (ACE); mRNA vaccine.
. 2022 Aug 10.
doi: 10.2169/internalmedicine.0104-22. Online ahead of print.
A Novel Development of Sarcoidosis following COVID-19 Vaccination and a Literature Review
Tadahisa Numakura[SUP] 1 [/SUP], Koji Murakami[SUP] 1 [/SUP], Tsutomu Tamada[SUP] 1 [/SUP], Chiaki Yamaguchi[SUP] 2 [/SUP], Chihiro Inoue[SUP] 3 [/SUP], Shinya Ohkouchi[SUP] 4 [/SUP], Naoki Tode[SUP] 1 [/SUP], Hirohito Sano[SUP] 1 [/SUP], Hiroyuki Aizawa[SUP] 1 [/SUP], Kei Sato[SUP] 1 [/SUP], Ayumi Mitsune[SUP] 1 [/SUP], Hajime Kurosawa[SUP] 4 [/SUP], Toru Nakazawa[SUP] 2 [/SUP], Hisatoshi Sugiura[SUP] 1 [/SUP]
Affiliations
- PMID: 35945009
- DOI: 10.2169/internalmedicine.0104-22
Abstract
BNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. However, immunological adverse events due to mRNA vaccines in real-world settings are not fully known. We herein report the novel development of sarcoidosis manifested as uveitis, bilateral hilar lymphadenopathy, angiotensin-converting enzyme elevation, and epithelioid and giant cell granuloma formation in the lung soon after the first BNT162b2 injection and review the current literature, including three reported cases of sarcoid-like reaction following COVID-19 vaccination.
Keywords: COVID-19; Sarcoidosis; Uveitis; angiotensin-converting enzyme (ACE); mRNA vaccine.